Jump to content

Drilldown: Medicines

Choose a table:


Medicines > classes : Antidepressant or Classic Psychedelic or Dissociative

Use the filters below to narrow your results.

generic:
brand:
None (87) · Anafranil (1) · Aurorix (1) · Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) · Delysid (historical, Sandoz, withdrawn 1965) (1) · DXM (1) · DXO (1) · Edronax (1) · Fetzima (1) · Ludiomil (1) · Marplan (1) · Nardil (1) · Norpramin (1) · Parnate (1) · Savella (1) · Serzone (1) · Spravato (1) · Stablon (1) · Surmontil (1) · Tofranil (1) · Valdoxan (1) · Vivactil (1) · Zoloft (1)
classes: (Click arrow to add another value)
mechanism:
5-HT2A agonist (26) · Potent 5-HT2A agonist (5) · LSD analogue; 5-HT2A agonist (4) · Prodrug of LSD; 5-HT2A agonist (4) · Irreversible non-selective MAO inhibitor (3) · NMDA antagonist (3) · Selective norepinephrine reuptake inhibitor (3) · Serotonin and norepinephrine reuptake inhibitor (3) · Contains LSA (2) · Contains mescaline (2) · NMDA antagonist; sigma receptor agonist (2) · Serotonin–norepinephrine reuptake inhibitor (2)
uses:
None (107) · Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) · Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1)
starting dose:
None (107) · 25 mg (1) · Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1)
preparations:
None (107) · 25 mg, 50 mg, 100 mg tablets; oral concentrate 20 mg/mL (1) · 28 mg/device (each dose uses 2 devices) (1)
fda max:
None (107) · 200 mg/d (1) · 84 mg per session (1)
routes:
None (105) · Intranasal (under direct medical supervision) (1) · Oral (3)
onset:
None (105) · 30–60 minutes (1) · Anxiolysis classically 3-4 weeks, continuing improvement to 8-12 weeks (1) · Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1) · Within hours of first administration (1)
duration:
None (105) · 8–12 hours (1) · Acute effect ~24 hours; cumulative effect builds with repeated dosing (1) · Chronic daily dosing (1) · Long (1)
halflife:
None (105) · 3–5 hours (1) · ~12 hours (1) · ~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1) · ~7-12 hours (1)
bioavailability:
None (105) · 70–90% (oral) (1) · Absolute bioavailability not precisely characterized; food modestly increases exposure (1) · ~48% intranasal (1) · ~50% (highly variable) (1)
pregnancy:
None (105) · Avoid; may cause fetal harm (1) · Category C (1) · Category C'"`UNIQ--ref-0000008F-QINU`"' (1) · Not established (1)
legal:
None (105) · Rx, Schedule III (US). REMS program required. (1) · Rx-only (1) · Rx-only in US (1) · Schedule I (United States) (1)

Showing below up to 109 results in range #1 to #109.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"